nodgoРоссийский журнал детской гематологии и онкологии (РЖДГиО)Russian Journal of Pediatric Hematology and Oncology2311-12672413-5496LTD “Graphica”10.21682/2311-1267-2021-8-4-71-80nodgo-774Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWSВозможности персонификации терапии в детской онкологии: обзор литературыOptions of precision medicine in pediatric oncology: literature reviewhttps://orcid.org/0000-0002-2003-0982ДиникинаЮ. В.DinikinaY. V.

Ю.В. Диникина: к.м.н., заведующая научно-исследовательской лабораторией детской нейроиммуноонкологии Центра персонализированной медицины и заведующая отделением химиотерапии онкогематологических заболеваний и трансплантации костного мозга для детейSPIN-код: 1776-6462

197341, Санкт-Петербург, ул. Аккуратова, 2

Yu.V. Dinikina: Cand. of Sci. (Med.), Head of the Laboratory of Pediatric Neuro-Immuno-Oncology of the Pesonalized Medicine Centre and Head of the Department of Chemotherapy for Hematologic Diseases and Bone Marrow Transplantation for ChildrenSPIN-code: 1776-6462

197341, S.-Petersburg, Akkuratova St., 2

dinikinayulia@mail.ruhttps://orcid.org/0000-0002-7471-7181БелогуроваМ. Б.BelogurovaM. B.

М.Б. Белогурова: д.м.н., профессор, ведущий научный сотрудник института онкологии и гематологииSPIN-код: 2627-4152

197341, Санкт-Петербург, ул. Аккуратова, 2

M.B. Belogurova: Dr. of Sci. (Med.), Professor, Leading Scientific Collaborator of Institution of HematologySPIN-code: 2627-4152

197341, S.-Petersburg, Akkuratova St., 2

deton.hospital31@inbox.ruФГБУ «Национальный медицинский исследовательский центр имени В.А. Алмазова» Минздрава РоссииРоссияAlmazov National Medical Research Centre, Ministry of Health of RussiaRussian Federation202120012022847180Copyright © Диникина Ю.В., Белогурова М.Б., 20222022Диникина Ю.В., Белогурова М.Б.Dinikina Y.V., Belogurova M.B.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nodgo.org/jour/article/view/774

За последние 50 лет значительно улучшилась выживаемость детей при онкологических заболеваниях, в первую очередь благодаря реализации кооперативных клинических исследований, позволивших стандартизировать и контролировать лечение детского рака. Использование комбинации различных методов противоопухолевого лечения с интенсификацией режимов химиотерапии для групп высокого риска на сегодняшний день позволяет достигать 70 % выживаемости детей по совокупности нозологий. Тем не менее крайне актуальными остаются вопросы повышения эффективности и снижения токсичности терапии у пациентов в группах неблагоприятного прогноза. Наиболее перспективным направлением является персонификация существующих опций лечения с использованием методов таргетной и иммунотерапии. В статье приведены международные данные по современным опциям персонализированной терапии в детской онкологии.

In the last 50 years there has been significant improvement in survival for children with cancer, achieved by the implementation of cooperative clinical research trials that found an opportunity to standardize and to control treatment of childhood cancer. Combined modalities in treatment approaches, intensification of chemotherapy regimens for high-risk disease allow to reach 70 % survival rate of all cases. Yet there is still a need to improve outcomes and decrease side effects of anticancer treatment in groups of unfavorable prognosis. The most promising point is personification of treatment with a special focus on targeted drug therapies and immunotherapy. We reviewed recent international advances and unique options in precision medicine for pediatric cancers.

детская онкологиягематологияперсонифицированная терапиясеквенирование нового поколениятаргетная терапияиммунотерапияхимиотерапияpediatric oncologyhematologyprecision medicinenext-generation sequencingtargeted therapyimmunotherapychemotherapyReferencesBurdach S.E.G., Westhoff M.-A., Steinhauser M.F., Debatin K.M. Precision medicine in pediatric oncology. Mol Cell Pediatr. 2018;5(6):1–15. doi:10.1186/s40348-018-0084.Burdach S.E.G., Westhoff M.-A., Steinhauser M.F., Debatin K.M. Precision medicine in pediatric oncology. Mol Cell Pediatr. 2018;5(6):1–15. doi:10.1186/s40348-018-0084.Steliarova-Foucher E., Colombet M., Ries L.A.G., Moreno F., Dolya A., Bray F., Hesseling P., Shin H.Y., Stiller C.A. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18(6):719–31. doi:10.1016/S1470-2045(17)30186-9.Steliarova-Foucher E., Colombet M., Ries L.A.G., Moreno F., Dolya A., Bray F., Hesseling P., Shin H.Y., Stiller C.A. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18(6):719–31. doi:10.1016/S1470-2045(17)30186-9.Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. ISBN 978-5-85502-251-3.Malignancies in Russia in 2018 (morbidity and mortality). A.D. Kaprin, V.V. Starinskiy, G.V. Petrova (eds.). M.: MNIOI named after P.A. Gertsen – affiliate FGBU NMIC radiology, Ministry of Health of Russia, 2019. (In Russ.). ISBN 978-5-85502-251-3.Childhood Cancer Statistics. CureSearch for Children’s Cancer. [Electronic resource]: https://curesearch.org/ (appeal date 2020).Childhood Cancer Statistics. CureSearch for Children’s Cancer. [Electronic resource]: https://curesearch.org/ (appeal date 2020).Kuhlen M., Borkhardt A. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr. 2015;174:987–97. doi:10.1007/s00431-015-2565-x.Kuhlen M., Borkhardt A. Cancer susceptibility syndromes in children in the area of broad clinical use of massive parallel sequencing. Eur J Pediatr. 2015;174:987–97. doi:10.1007/s00431-015-2565-x.Knapke S., Zelley K., Nichols K.E., Kohlmann W., Schiffman J.D. Identification, management, and evaluation of children with cancerpredisposition syndromes. Am Soc Clin Oncol Educ Book. 2012:576–84. doi:10.14694/EdBook_AM.2012.32.8.Knapke S., Zelley K., Nichols K.E., Kohlmann W., Schiffman J.D. Identification, management, and evaluation of children with cancerpredisposition syndromes. Am Soc Clin Oncol Educ Book. 2012:576–84. doi:10.14694/EdBook_AM.2012.32.8.Gupta S., Howard S.C., Hunger S.P., Antillon F.G., Metzger M.L., Israels T., Harif M., Rodriguez-Galindo C., Gelband H., Jha P., Sankaranarayanan R., Horton S. Treating Childhood Cancer in Lowand Middle-Income Countries. In: Disease Control Priorities, 3rd ed. Washigton/USA: DC: World Bank, 2015. Pp. 121–46. doi:10.1596/978-1-4648-0349-9_ch7.Gupta S., Howard S.C., Hunger S.P., Antillon F.G., Metzger M.L., Israels T., Harif M., Rodriguez-Galindo C., Gelband H., Jha P., Sankaranarayanan R., Horton S. Treating Childhood Cancer in Lowand Middle-Income Countries. In: Disease Control Priorities, 3rd ed. Washigton/USA: DC: World Bank, 2015. Pp. 121–46. doi:10.1596/978-1-4648-0349-9_ch7.German Childhood Cancer Registry. [Electronic resource]: https://www.kinderkrebsregister.de (appeal date 19.02.2018).German Childhood Cancer Registry. [Electronic resource]: https://www.kinderkrebsregister.de (appeal date 19.02.2018).American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.American Cancer Society. Cancer Facts and Figures 2016. Atlanta, GA: American Cancer Society, 2016.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013.Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. doi:10.1016/j.cell.2011.02.013.Mody R.J., Prensner J.R., Everett J., Parsons D.W., Chinnaiyan A.M. Precision medicine in pediatric oncology: lessons learned and next steps. Pediatr Blood Cancer. 2017;64(3):10.1002/pbc.26288. doi:10.1002/pbc.26288.Mody R.J., Prensner J.R., Everett J., Parsons D.W., Chinnaiyan A.M. Precision medicine in pediatric oncology: lessons learned and next steps. Pediatr Blood Cancer. 2017;64(3):10.1002/pbc.26288. doi:10.1002/pbc.26288.Mody R.J., Wu Y.M., Lonigro R.J., Cao X., Roychowdhury S., Vats P., Frank K.M., Prensner J.R., Asangani I., Palanisamy N., Dillman J.R., Rabah R.M., Kunju L.P., Everett J., Raymond V.M., Ning Y., Su F., Wang R., Stoffel E.M., Innis J.W., Roberts J.S., Robertson P.L., Yanik G., Chamdin A., Connelly J.A., Choi S., Harris A.C., Kitko K., Rao R.J., Levine J.E., Castle V.P., Hutchinson R.J., Talpaz M., Robinson D.R., Chinnaiyan A.M. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. J Am Med Assoc. 2015;314(9):913–25. doi:10.1001/jama.2015.10080.Mody R.J., Wu Y.M., Lonigro R.J., Cao X., Roychowdhury S., Vats P., Frank K.M., Prensner J.R., Asangani I., Palanisamy N., Dillman J.R., Rabah R.M., Kunju L.P., Everett J., Raymond V.M., Ning Y., Su F., Wang R., Stoffel E.M., Innis J.W., Roberts J.S., Robertson P.L., Yanik G., Chamdin A., Connelly J.A., Choi S., Harris A.C., Kitko K., Rao R.J., Levine J.E., Castle V.P., Hutchinson R.J., Talpaz M., Robinson D.R., Chinnaiyan A.M. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. J Am Med Assoc. 2015;314(9):913–25. doi:10.1001/jama.2015.10080.Gröbner S.N., Worst B.C., Weischenfeldt J., Buchhalter I., Kleinheinz K., Rudneva A., Johann P.D., Balasubramanian G.P., Segura-Wang M., Brabetz S., Bender S., Hutter B., Sturm D., Pfaff E., Hübschmann D., Zipprich G., Heinold M., Eils J., Lawerenz C., Lambo S.E., Waszak S., Blattmann C., Borkhardt A., Kuhlen M., Eggert A., Fulda S., Gessler M., Wegert J., Kappler R., Baumhoer D., Burdach S., Kirschner-Schwabe R., Kontny U., Kulozik A.E., Lohmann D., Hettmer S., Eckert C., Bielack S., Nathrath M., Niemeyer C., Richter G.H., Schulte J., Siebert R., Westermann F., Molenaar J.J., Vassal G., Witt H., Zapatka M., Burkhardt B., Kratz C.P., Witt O., Van Tilburg C.M., Kramm C.M., Fleischhack G., Dirksen U., Rutkowski S., Frühwald M., Von Hoff K., Wolf S., Klingebiel T., Koscielniak E., Landgraf P., Koster J., Resnick A.C., Zhang J., Liu Y., Zhou X., Waanders A.J., Zwijnenburg D.A., Raman P., Brors B., Weber U.D., Northcott P.A., Pajtler K.A., Kool M., Piro R.M., Korbel J.O., Schlesner M., Eils R., Jones D.T.W., Lichter P., Chavez L., Pfister S.M. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321–7. doi:10.1038/nature25480.Gröbner S.N., Worst B.C., Weischenfeldt J., Buchhalter I., Kleinheinz K., Rudneva A., Johann P.D., Balasubramanian G.P., Segura-Wang M., Brabetz S., Bender S., Hutter B., Sturm D., Pfaff E., Hübschmann D., Zipprich G., Heinold M., Eils J., Lawerenz C., Lambo S.E., Waszak S., Blattmann C., Borkhardt A., Kuhlen M., Eggert A., Fulda S., Gessler M., Wegert J., Kappler R., Baumhoer D., Burdach S., Kirschner-Schwabe R., Kontny U., Kulozik A.E., Lohmann D., Hettmer S., Eckert C., Bielack S., Nathrath M., Niemeyer C., Richter G.H., Schulte J., Siebert R., Westermann F., Molenaar J.J., Vassal G., Witt H., Zapatka M., Burkhardt B., Kratz C.P., Witt O., Van Tilburg C.M., Kramm C.M., Fleischhack G., Dirksen U., Rutkowski S., Frühwald M., Von Hoff K., Wolf S., Klingebiel T., Koscielniak E., Landgraf P., Koster J., Resnick A.C., Zhang J., Liu Y., Zhou X., Waanders A.J., Zwijnenburg D.A., Raman P., Brors B., Weber U.D., Northcott P.A., Pajtler K.A., Kool M., Piro R.M., Korbel J.O., Schlesner M., Eils R., Jones D.T.W., Lichter P., Chavez L., Pfister S.M. The landscape of genomic alterations across childhood cancers. Nature. 2018;555(7696):321–7. doi:10.1038/nature25480.Worst B.C., van Tilburg C.M., Balasubramanian G.P., Fiesel P., Witt R., Freitag A., Boudalil M., Previti C., Wolf S., Schmidt S., Chotewutmontri S., Bewerunge-Hudler M., Schick M., Schlesner M., Hutter B., Taylor L., Borst T., Sutter C., Bartram C.R., Milde T., Pfaff E., Kulozik A.E., von Stackelberg A., Meisel R., Borkhardt A., Reinhardt D., Klusmann J.H., Fleischhack G., Tippelt S., Dirksen U., Jürgens H., Kramm C., von Bueren A.O., Westermann F., Fischer M., Burkhardt B., Wößmann W., Nathrath M., Bielack S.S., Frühwald M.C., Fulda S., Klingebiel T., Koscielniak E., Schwab M., Tremmel R., Hernáiz Driever P., Schulte J.H., Brors B., von Deimling A., Lichter P., Eggert A., Capper D., Pfister S.M., Jones D.T.W., Witt O. Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016;65:91–101. doi:10.1016/j.ejca.2016.06.009.Worst B.C., van Tilburg C.M., Balasubramanian G.P., Fiesel P., Witt R., Freitag A., Boudalil M., Previti C., Wolf S., Schmidt S., Chotewutmontri S., Bewerunge-Hudler M., Schick M., Schlesner M., Hutter B., Taylor L., Borst T., Sutter C., Bartram C.R., Milde T., Pfaff E., Kulozik A.E., von Stackelberg A., Meisel R., Borkhardt A., Reinhardt D., Klusmann J.H., Fleischhack G., Tippelt S., Dirksen U., Jürgens H., Kramm C., von Bueren A.O., Westermann F., Fischer M., Burkhardt B., Wößmann W., Nathrath M., Bielack S.S., Frühwald M.C., Fulda S., Klingebiel T., Koscielniak E., Schwab M., Tremmel R., Hernáiz Driever P., Schulte J.H., Brors B., von Deimling A., Lichter P., Eggert A., Capper D., Pfister S.M., Jones D.T.W., Witt O. Next-generation personalised medicine for high-risk paediatric cancer patients – the INFORM pilot study. Eur J Cancer. 2016;65:91–101. doi:10.1016/j.ejca.2016.06.009.Parson D.W., Roy A., Yang Y., Wang T., Scollon S., Bergstrom K., Kerstein R.A., Gutierrez S., Petersen A.K., Bavle A., Lin F.Y., Lopez-Terrada D.H., Monzon F.A., Hicks M.J., Eldin K.W., Quintanilla N.M., Adesina A.M., Mohila C.A., Whitehead W., Jea A., Vasudevan S.A., Nuchtern J.G., Ramamurthy U., McGuire A.L., Hilsenbeck S.G., Reid J.G., Muzny D.M., Wheeler D.A., Berg S.L., Chintagumpala M.M., Eng C.M., Gibbs R.A., Plon S.E. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616–24. doi:10.1001/jamaoncol.2015.5699.Parson D.W., Roy A., Yang Y., Wang T., Scollon S., Bergstrom K., Kerstein R.A., Gutierrez S., Petersen A.K., Bavle A., Lin F.Y., Lopez-Terrada D.H., Monzon F.A., Hicks M.J., Eldin K.W., Quintanilla N.M., Adesina A.M., Mohila C.A., Whitehead W., Jea A., Vasudevan S.A., Nuchtern J.G., Ramamurthy U., McGuire A.L., Hilsenbeck S.G., Reid J.G., Muzny D.M., Wheeler D.A., Berg S.L., Chintagumpala M.M., Eng C.M., Gibbs R.A., Plon S.E. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016;2(5):616–24. doi:10.1001/jamaoncol.2015.5699.Allen C.E., Laetsch T.W., Mody R., Irwin M.S., Lim M.S., Adamson P.C., Seibel N.L., Parsons D.W., Cho Y.J., Janeway K. Target and agent prioritization for the Children’s Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017;109(5):djw274. doi:10.1093/jnci/djw274.Allen C.E., Laetsch T.W., Mody R., Irwin M.S., Lim M.S., Adamson P.C., Seibel N.L., Parsons D.W., Cho Y.J., Janeway K. Target and agent prioritization for the Children’s Oncology Group-National Cancer Institute Pediatric MATCH Trial. J Natl Cancer Inst. 2017;109(5):djw274. doi:10.1093/jnci/djw274.Downing J.R., Wilson R.K., Zhang J., Mardis E.R., Pui C.H., Ding L., Ley T.J., Evans W.E. The pediatric cancer genome project. Nat Genet. 2012;44:619–22. doi:10.1038/ng.2287.Downing J.R., Wilson R.K., Zhang J., Mardis E.R., Pui C.H., Ding L., Ley T.J., Evans W.E. The pediatric cancer genome project. Nat Genet. 2012;44:619–22. doi:10.1038/ng.2287.Harris M.H., DuBois S.G., Glade Bender J.L., Kim A., Crompton B.D., Parker E., Dumont I.P., Hong A.L., Guo D., Church A., Stegmaier K., Roberts C.W.M., Shusterman S., London W.B., MacConaill L.E., Lindeman N.I., Diller L., Rodriguez-Galindo C., Janeway K.A. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016;2(5):608–15. doi:10.1001/jamaoncol.2015.5689.Harris M.H., DuBois S.G., Glade Bender J.L., Kim A., Crompton B.D., Parker E., Dumont I.P., Hong A.L., Guo D., Church A., Stegmaier K., Roberts C.W.M., Shusterman S., London W.B., MacConaill L.E., Lindeman N.I., Diller L., Rodriguez-Galindo C., Janeway K.A. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016;2(5):608–15. doi:10.1001/jamaoncol.2015.5689.Forrest S., Georrger B., Janeway K.A. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30:17–24. doi:10.1097/MOP.0000000000000570.Forrest S., Georrger B., Janeway K.A. Precision medicine in pediatric oncology. Curr Opin Pediatr. 2018;30:17–24. doi:10.1097/MOP.0000000000000570.Pincez T., Clement N., Lapouble E. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. 2017;64(6):1–9. doi:10.1002/pbc.26365.Pincez T., Clement N., Lapouble E. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatr Blood Cancer. 2017;64(6):1–9. doi:10.1002/pbc.26365.Oberg J.A., Glade Bender J.L., Sulis M.L., Pendrick D., Sireci A.N., Hsiao S.J., Turk A.T., Dela Cruz F.S., Hibshoosh H., Remotti H., Zylber R.J., Pang J., Diolaiti D., Koval C., Andrews S.J., Garvin J.H., Yamashiro D.J., Chung W.K., Emerson S.G., Nagy P.L., Mansukhani M.M., Kung A.L. Implementation of next generation swquencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8(1):133. doi:10.1186/s13073-016-0389-6.Oberg J.A., Glade Bender J.L., Sulis M.L., Pendrick D., Sireci A.N., Hsiao S.J., Turk A.T., Dela Cruz F.S., Hibshoosh H., Remotti H., Zylber R.J., Pang J., Diolaiti D., Koval C., Andrews S.J., Garvin J.H., Yamashiro D.J., Chung W.K., Emerson S.G., Nagy P.L., Mansukhani M.M., Kung A.L. Implementation of next generation swquencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Med. 2016;8(1):133. doi:10.1186/s13073-016-0389-6.Harttrampf A.C., Lacroix L., Deloger M., Deschamps F., Puget S., Auger N., Vielh P., Varlet P., Balogh Z., Abbou S., Allorant A., Valteau-Couanet D., Sarnacki S., Gamiche-Rolland L., Meurice G., MinardColin V., Grill J., Brugieres L., Dufour C., Gaspar N., Michiels S., Vassal G., Soria J.C., Geoerger B. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017;23(20):6101–12. doi:10.1158/1078-0432.Harttrampf A.C., Lacroix L., Deloger M., Deschamps F., Puget S., Auger N., Vielh P., Varlet P., Balogh Z., Abbou S., Allorant A., Valteau-Couanet D., Sarnacki S., Gamiche-Rolland L., Meurice G., MinardColin V., Grill J., Brugieres L., Dufour C., Gaspar N., Michiels S., Vassal G., Soria J.C., Geoerger B. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial. Clin Cancer Res. 2017;23(20):6101–12. doi:10.1158/1078-0432.Schramm A., Koster J., Assenov Y., Althoff K., Peifer M., Mahlow E., Odersky A., Beisser D., Ernst C., Henssen A.G., Stephan H., Schröder C., Heukamp L., Engesser A., Kahlert Y., Theissen J., Hero B., Roels F., Altmüller J., Nürnberg P., Astrahantseff K., Gloeckner C., De Preter K., Plass C., Lee S., Lode H.N., Henrich K.O., Gartlgruber M., Speleman F., Schmezer P., Westermann F., Rahmann S., Fisher M., Eggert A., Schulte J.H. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872–7. doi:10.138/ng.3349.Schramm A., Koster J., Assenov Y., Althoff K., Peifer M., Mahlow E., Odersky A., Beisser D., Ernst C., Henssen A.G., Stephan H., Schröder C., Heukamp L., Engesser A., Kahlert Y., Theissen J., Hero B., Roels F., Altmüller J., Nürnberg P., Astrahantseff K., Gloeckner C., De Preter K., Plass C., Lee S., Lode H.N., Henrich K.O., Gartlgruber M., Speleman F., Schmezer P., Westermann F., Rahmann S., Fisher M., Eggert A., Schulte J.H. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872–7. doi:10.138/ng.3349.Zhang J., Walsh M.F., Wu G., Edmonson M.N., Gruber T.A., Easton J., Hedges D., Ma X., Zhou X., Yergeau D.A., Wikinson M.R., Vadodaria B., Chen X., McGee R.B., Hines-Dowell S., Nuccio R., Quinn E., Shurtleff S.A., Rusch M., Patel A., Becksfort J.B., Wang S., Weaver M.S., Ding L., Mardis E.R., Wilson R.K., Gajjar A., Ellison D.W., Pappo A.S., Pui C., Nichols K.E., Downing J.R. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46. doi:10.1056/NEJMoa1508054.Zhang J., Walsh M.F., Wu G., Edmonson M.N., Gruber T.A., Easton J., Hedges D., Ma X., Zhou X., Yergeau D.A., Wikinson M.R., Vadodaria B., Chen X., McGee R.B., Hines-Dowell S., Nuccio R., Quinn E., Shurtleff S.A., Rusch M., Patel A., Becksfort J.B., Wang S., Weaver M.S., Ding L., Mardis E.R., Wilson R.K., Gajjar A., Ellison D.W., Pappo A.S., Pui C., Nichols K.E., Downing J.R. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336–46. doi:10.1056/NEJMoa1508054.Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hedge M., Lyon E., Spector E., Voelkerding K., Rehm H.L. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. doi:10.1038/gim.2015.30.Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hedge M., Lyon E., Spector E., Voelkerding K., Rehm H.L. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. doi:10.1038/gim.2015.30.Tran T.H., Shah A.T., Loh M.L. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. Clin Cancer Research. 2017;23(18):5329–38. doi:10.1158/1078-0432.CCR-16-0115.Tran T.H., Shah A.T., Loh M.L. Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. Clin Cancer Research. 2017;23(18):5329–38. doi:10.1158/1078-0432.CCR-16-0115.Korshunov A., Chavez L., Northcott P.A., Sharma T., Ryzhova M., Jones D.T.W., von Deimling A., Pfister S.M., Kool M. DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathol. 2017;134:965–7. doi:10.1007/s00401-017-1776-9.Korshunov A., Chavez L., Northcott P.A., Sharma T., Ryzhova M., Jones D.T.W., von Deimling A., Pfister S.M., Kool M. DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathol. 2017;134:965–7. doi:10.1007/s00401-017-1776-9.Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., Antonarakis E.S., Azad N.S., Bardelli A., Brem H., Cameron J.L., Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R., Goggins M., Hogarty M.D., Holdhoff M., Hong S.M., Jiao Y., Juhl H.H., Kim J.J., Siravegna G., Laheru D.A., Lauricella C., Lim M., Lipson E.J., Nagahashi M.S.K., Netto G.J., Oliner K.S., Olivi A., Olsson L., Riggins G.J., SartoreBianchi A., Schmidt K., le-Ming S., Oba-Shinjo S.M., Siena S., Theodorescu D., Tie J., Harkins T.T., Veronese S., Wang T.L., Weingart J.D., Wolfgang C.L., Wood L.D., Xing D., Hruban R.H., Wu J., Allen P.J., Schmidt C.M., Choti M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Papadopoulos N., Diaz L.A. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224. doi:10.1126/scitranslmed.3007094.Bettegowda C., Sausen M., Leary R.J., Kinde I., Wang Y., Agrawal N., Bartlett B.R., Wang H., Luber B., Alani R.M., Antonarakis E.S., Azad N.S., Bardelli A., Brem H., Cameron J.L., Lee C.C., Fecher L.A., Gallia G.L., Gibbs P., Le D., Giuntoli R., Goggins M., Hogarty M.D., Holdhoff M., Hong S.M., Jiao Y., Juhl H.H., Kim J.J., Siravegna G., Laheru D.A., Lauricella C., Lim M., Lipson E.J., Nagahashi M.S.K., Netto G.J., Oliner K.S., Olivi A., Olsson L., Riggins G.J., SartoreBianchi A., Schmidt K., le-Ming S., Oba-Shinjo S.M., Siena S., Theodorescu D., Tie J., Harkins T.T., Veronese S., Wang T.L., Weingart J.D., Wolfgang C.L., Wood L.D., Xing D., Hruban R.H., Wu J., Allen P.J., Schmidt C.M., Choti M.A., Velculescu V.E., Kinzler K.W., Vogelstein B., Papadopoulos N., Diaz L.A. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra224. doi:10.1126/scitranslmed.3007094.Kurihara S., Ueda Y., Onitake Y., Sueda T., Ohta E., Morihara N., Hirano S., Irisuna F., Hiyama E. Circulating free DNA as noninvasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg. 2015;50(12):2094–7. doi:10.1016/j.jpedsurg.2015.08.033.Kurihara S., Ueda Y., Onitake Y., Sueda T., Ohta E., Morihara N., Hirano S., Irisuna F., Hiyama E. Circulating free DNA as noninvasive diagnostic biomarker for childhood solid tumors. J Pediatr Surg. 2015;50(12):2094–7. doi:10.1016/j.jpedsurg.2015.08.033.Klco J.M., Miller C.A., Griffith M., Petti A., Spencer D.H., Ketkar-Kulkarni S., Wartman L.D., Christopher M., Lamprecht T.L., Helton N.M., Duncavage E.J., Payton J.E., Baty J., Heath S.E., Griffith O.L., Shen D., Hundal J., Chang G.S., Fulton R., O’Laughlin M., Fronick C., Magrini V., Demeter R.T., Larson D.E., Kukarni S., Ozenberger B.A., Welch J.S., Walter M.J., Graubert T.A., Westervelt P., Radich J.P., Link D.C., Mardis E.R., DiPersio J.F., Wilson R.K., Ley T.J. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. J Am Med Assoc. 2015;314(8):811–22. doi:10.1001/jama.2015.9643.Klco J.M., Miller C.A., Griffith M., Petti A., Spencer D.H., Ketkar-Kulkarni S., Wartman L.D., Christopher M., Lamprecht T.L., Helton N.M., Duncavage E.J., Payton J.E., Baty J., Heath S.E., Griffith O.L., Shen D., Hundal J., Chang G.S., Fulton R., O’Laughlin M., Fronick C., Magrini V., Demeter R.T., Larson D.E., Kukarni S., Ozenberger B.A., Welch J.S., Walter M.J., Graubert T.A., Westervelt P., Radich J.P., Link D.C., Mardis E.R., DiPersio J.F., Wilson R.K., Ley T.J. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. J Am Med Assoc. 2015;314(8):811–22. doi:10.1001/jama.2015.9643.Stadt U.Z., Escherich G., Indenbirken D., Alawi M., Adao M., Horstmann M.A. Rapid capture next-generation sequencing in clinical diagnostics of kinase pathway aberrations in B-cell precursor ALL. Pediatr Blood Cancer. 2016;63(7):1283–6. doi:10.1002/pbc.25975.Stadt U.Z., Escherich G., Indenbirken D., Alawi M., Adao M., Horstmann M.A. Rapid capture next-generation sequencing in clinical diagnostics of kinase pathway aberrations in B-cell precursor ALL. Pediatr Blood Cancer. 2016;63(7):1283–6. doi:10.1002/pbc.25975.Hayashi M., Chu D., Meyer C.F., Llosa N.J., McCarty G., Morris C.D., Levin A.S., Wolinsky J.P., Albert C.M., Steppan D.A., Park B.H., Loeb D.M. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer. 2016;122:3015–23. doi:10.1002/cncr.30144.Hayashi M., Chu D., Meyer C.F., Llosa N.J., McCarty G., Morris C.D., Levin A.S., Wolinsky J.P., Albert C.M., Steppan D.A., Park B.H., Loeb D.M. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer. 2016;122:3015–23. doi:10.1002/cncr.30144.Chakravadhanula M., Tembe W., Legendre C., Carpentieri D., Liang W.S., Bussey K.J., Carpen J., Berens M.E., Bhardwaj R.D. Detection of an atypical teratoid rhabdoid brain tumor gene deletion in circulating blood using next-generation sequencing. J Child Neurol. 2014;29:NP81–5. doi:10.1177/0883073813503904.Chakravadhanula M., Tembe W., Legendre C., Carpentieri D., Liang W.S., Bussey K.J., Carpen J., Berens M.E., Bhardwaj R.D. Detection of an atypical teratoid rhabdoid brain tumor gene deletion in circulating blood using next-generation sequencing. J Child Neurol. 2014;29:NP81–5. doi:10.1177/0883073813503904.Elie V., de Beaumais T., Fakhoury M., Jacqz-Aigrain E. Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and antiinflammatory drugs. Pharmacogenomics. 2011;12(6):827–43. doi:10.2217/pgs.11.19.Elie V., de Beaumais T., Fakhoury M., Jacqz-Aigrain E. Pharmacogenetics and individualized therapy in children: immunosuppressants, antidepressants, anticancer and antiinflammatory drugs. Pharmacogenomics. 2011;12(6):827–43. doi:10.2217/pgs.11.19.Shultz K.R., Carroll A., Heerema N.A., Bowman W.P., Aledo A., Slayton B., Sather H., Devidas M., Zheng H.W., Davies S.M., Gaynon P.S., Trigg M., Rutledge R., Jorstad D., Winick N., Borowitz M.J., Hunger S.P., Carroll W.L., Camitta B. Long-term followup of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28:1467–71. doi:10.1038/leu.2014.30.Shultz K.R., Carroll A., Heerema N.A., Bowman W.P., Aledo A., Slayton B., Sather H., Devidas M., Zheng H.W., Davies S.M., Gaynon P.S., Trigg M., Rutledge R., Jorstad D., Winick N., Borowitz M.J., Hunger S.P., Carroll W.L., Camitta B. Long-term followup of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children’s Oncology Group study AALL0031. Leukemia. 2014;28:1467–71. doi:10.1038/leu.2014.30.Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., Lock R., Carol H., Reynolds C.P., Maris J.M., Keir S.T., Billups C.A., Smith M.A. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:799–805. doi:10.1002/pbc.21296.Houghton P.J., Morton C.L., Kolb E.A., Gorlick R., Lock R., Carol H., Reynolds C.P., Maris J.M., Keir S.T., Billups C.A., Smith M.A. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:799–805. doi:10.1002/pbc.21296.Vo K.T., Karski E.E., Nasholm N.M., Allen S., Hollinger F., Gustafson W.C., Long-Boyle J.R., Shiboski S., Matthay K.K., DuBois S.G. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017;8(14):23851–61. doi:10.18632/oncotarget.12904.Vo K.T., Karski E.E., Nasholm N.M., Allen S., Hollinger F., Gustafson W.C., Long-Boyle J.R., Shiboski S., Matthay K.K., DuBois S.G. Phase 1 study of sirolimus in combination with oral cyclophosphamide and topotecan in children and young adults with relapsed and refractory solid tumors. Oncotarget. 2017;8(14):23851–61. doi:10.18632/oncotarget.12904.Johnsen J.I., Segerstrom L., Orrego A., Elfman L., Henriksson M., Kagedal B., Eksborg S., Sveinbjörnsson B., Kogner P. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27:2910–22. doi:10.1038/sj.onc.1210938.Johnsen J.I., Segerstrom L., Orrego A., Elfman L., Henriksson M., Kagedal B., Eksborg S., Sveinbjörnsson B., Kogner P. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene. 2008;27:2910–22. doi:10.1038/sj.onc.1210938.Perry J.A., Kiezun A., Tonzi P., Allen E.M., Carter S.L., Baca S.C., Cowley G.S., Bhatt A.S., Rheinbay E., Pedamallu C.S., Helman E., Taylor-Weiner A., McKenna A., DeLuca D.S., Lawrence M.S., Ambrogio L., Sougnez C., Sivachenko A., Walensky L.D., Wagle N., Mora J., de Torres C., Lavarino C., Aguiar S., Yunes J.A., Brandalise S.R., Mercado-Celis G.E., Melendez-Zajgla J., Cardenas-Cardos R., Velasco-Hidalgo L., Roberts C.W.M., Garraway L.A., Rodriguez-Galindo C., Gabriel S.B., Lander E.S., Golub T.R., Orkin S.H., Getz G., Janeway K.A. Complementary genomic approaches highlight the PICK/ mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA. 2014;111(51):E5564–73. doi:10.1073/pnas.1419260111.Perry J.A., Kiezun A., Tonzi P., Allen E.M., Carter S.L., Baca S.C., Cowley G.S., Bhatt A.S., Rheinbay E., Pedamallu C.S., Helman E., Taylor-Weiner A., McKenna A., DeLuca D.S., Lawrence M.S., Ambrogio L., Sougnez C., Sivachenko A., Walensky L.D., Wagle N., Mora J., de Torres C., Lavarino C., Aguiar S., Yunes J.A., Brandalise S.R., Mercado-Celis G.E., Melendez-Zajgla J., Cardenas-Cardos R., Velasco-Hidalgo L., Roberts C.W.M., Garraway L.A., Rodriguez-Galindo C., Gabriel S.B., Lander E.S., Golub T.R., Orkin S.H., Getz G., Janeway K.A. Complementary genomic approaches highlight the PICK/ mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci USA. 2014;111(51):E5564–73. doi:10.1073/pnas.1419260111.Zhao Y., Adjei A.A. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11(7):385-400. doi:10.1038/nrclinonc.2014.83.Zhao Y., Adjei A.A. The clinical development of MEK inhibitors. Nat Rev Clin Oncol. 2014;11(7):385-400. doi:10.1038/nrclinonc.2014.83.Lu C., Zhang J., Nagahawatte P., Easton J., Lee S., Liu Z., Ding L., Wyczalkowski M.A., Valentine M., Navid F., Mulder H., Tatevossian R.G., Dalton J., Davenport J., Yin Z., Edmonson M., Rusch M., Wu G., Li Y., Parker M., Hedlund E., Shurtleff S., Raimondi S., Bhavin V., Donald Y., Mardis E.R., Wilson R.K., Evans W.E., Ellison D.W., Pounds S., Dyer M., Downing J.R., Pappo A., Bahrami A. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135(3):816–23. doi:10.1038/jid.2014.425.Lu C., Zhang J., Nagahawatte P., Easton J., Lee S., Liu Z., Ding L., Wyczalkowski M.A., Valentine M., Navid F., Mulder H., Tatevossian R.G., Dalton J., Davenport J., Yin Z., Edmonson M., Rusch M., Wu G., Li Y., Parker M., Hedlund E., Shurtleff S., Raimondi S., Bhavin V., Donald Y., Mardis E.R., Wilson R.K., Evans W.E., Ellison D.W., Pounds S., Dyer M., Downing J.R., Pappo A., Bahrami A. The genomic landscape of childhood and adolescent melanoma. J Invest Dermatol. 2015;135(3):816–23. doi:10.1038/jid.2014.425.Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.I., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese M.L., Tabernero J., Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36. doi:10.1056/NEJMoa1502309.Hyman D.M., Puzanov I., Subbiah V., Faris J.E., Chau I., Blay J.I., Wolf J., Raje N.S., Diamond E.L., Hollebecque A., Gervais R., Elez-Fernandez M.E., Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese M.L., Tabernero J., Baselga J. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–36. doi:10.1056/NEJMoa1502309.Mosse Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J., Rolland D., Balis F.M., Maris J.M., Weigel B.J., Ingle A.M., Ahren C., Adamson P.C., Blaney S.M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80. doi:10.1016/S1470-2045(13)70095-0.Mosse Y.P., Lim M.S., Voss S.D., Wilner K., Ruffner K., Laliberte J., Rolland D., Balis F.M., Maris J.M., Weigel B.J., Ingle A.M., Ahren C., Adamson P.C., Blaney S.M. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children’s Oncology Group phase 1 consortium study. Lancet Oncol. 2013;14(6):472–80. doi:10.1016/S1470-2045(13)70095-0.Doebele R.C., Davis L.E., Vaishnavi A., Le A.T., Estrada-Bernal A., Keysar S., Jimeno A., Varella-Garcia M., Aisner D.L., Li Y., Stephens P.J., Morosini D., Tuch B.B., Fernandes M., Nanda N., Low J.A. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5(10):1049–57. doi:10.1158/2159-8290.CD-15-0443.Doebele R.C., Davis L.E., Vaishnavi A., Le A.T., Estrada-Bernal A., Keysar S., Jimeno A., Varella-Garcia M., Aisner D.L., Li Y., Stephens P.J., Morosini D., Tuch B.B., Fernandes M., Nanda N., Low J.A. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 2015;5(10):1049–57. doi:10.1158/2159-8290.CD-15-0443.Gajjar A., Stewart C.F., Ellison D.W., Kaste S., Kun L.E., Packer R.J., Goldman S., Chintagumpala M., Wallace D., Takebe N., Boyett J.M., Gilbertson R.J., Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19(22):6305–12. doi:10.1158/1078-04.32.CCR-13-1425.Gajjar A., Stewart C.F., Ellison D.W., Kaste S., Kun L.E., Packer R.J., Goldman S., Chintagumpala M., Wallace D., Takebe N., Boyett J.M., Gilbertson R.J., Curran T. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19(22):6305–12. doi:10.1158/1078-04.32.CCR-13-1425.Brenner J.C., Feng F.Y., Han S., Patel S., Goyal S.V., Bou-Maroun L.M., Liu M., Lonigro R., Prensner J.R., Tomlins S.A., Chinnaiyan A.M. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res. 2012;72(7):1608–13. doi:10.1158/0008-5472.CAN-11-3648.Brenner J.C., Feng F.Y., Han S., Patel S., Goyal S.V., Bou-Maroun L.M., Liu M., Lonigro R., Prensner J.R., Tomlins S.A., Chinnaiyan A.M. PARP-1 inhibition as a targeted strategy to treat Ewing’s sarcoma. Cancer Res. 2012;72(7):1608–13. doi:10.1158/0008-5472.CAN-11-3648.Rader J., Russell M.R., Hart L.S., Nakazawa M.S., Belcastro L.T., Martinez D., Li Y., Carpenter E.L., Attiyeh E.F., Diskin S.J., Kim S., Parasuraman S., Caponigro G., Schnepp R.W., Wood A.C., Pawel B., Cole K.A., Maris J.M. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–82. doi:10.1158/1078-0432.CCR-13-1675.Rader J., Russell M.R., Hart L.S., Nakazawa M.S., Belcastro L.T., Martinez D., Li Y., Carpenter E.L., Attiyeh E.F., Diskin S.J., Kim S., Parasuraman S., Caponigro G., Schnepp R.W., Wood A.C., Pawel B., Cole K.A., Maris J.M. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013;19(22):6173–82. doi:10.1158/1078-0432.CCR-13-1675.Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S., Tang Y., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F., Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J., Liu K.W., Wechsler-Reya R., Weiss W.A., Swartling F.J., Kieran M.W., Bradner J.E., Beroukhim R., Cho Y.J. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20(4):912–25. doi:10.1158/1078-0432.CCR-13-2281.Bandopadhayay P., Bergthold G., Nguyen B., Schubert S., Gholamin S., Tang Y., Bolin S., Schumacher S.E., Zeid R., Masoud S., Yu F., Vue N., Gibson W.J., Paolella B.R., Mitra S.S., Cheshier S.H., Qi J., Liu K.W., Wechsler-Reya R., Weiss W.A., Swartling F.J., Kieran M.W., Bradner J.E., Beroukhim R., Cho Y.J. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20(4):912–25. doi:10.1158/1078-0432.CCR-13-2281.DuBois S.G., Marachelian A., Fox E., Kudgus R.A., Reid J.M., Groshen S., Malvar J., Bagatell R., Wagner L., Maris J.M., Hawkins R., Courtier J., Lai H., Goodarzian F., Shimada H., Czarnecki S., Tsao-Wei D., Matthay K.K., Mosse Y.P. Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016;34(12):1368–75. doi:10.1200/JCO.2015.65.4889.DuBois S.G., Marachelian A., Fox E., Kudgus R.A., Reid J.M., Groshen S., Malvar J., Bagatell R., Wagner L., Maris J.M., Hawkins R., Courtier J., Lai H., Goodarzian F., Shimada H., Czarnecki S., Tsao-Wei D., Matthay K.K., Mosse Y.P. Phase I study of the aurora A kinase inhibitor alisertib in combination with irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma: a NANT (New Approaches to Neuroblastoma Therapy) Trial. J Clin Oncol. 2016;34(12):1368–75. doi:10.1200/JCO.2015.65.4889.Li S.Q., Cheuk A.T., Shern J.F., Song Y.K., Hurd L., Liao H., Wei J.S., Khan J. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013;8(10):e76551. doi:10.1371/journal.pone.0076551.Li S.Q., Cheuk A.T., Shern J.F., Song Y.K., Hurd L., Liao H., Wei J.S., Khan J. Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534). PLoS One. 2013;8(10):e76551. doi:10.1371/journal.pone.0076551.Tarlock K., Chang B., Cooper T., Gross T., Gupta S., Neuorf S., Adlard K., Ho P.A., McGoldrick S., Watt T., Templeman T., Sisler I., Garee A., Thomson B., Woolfrey A., Estey E., Meshinchi S., Pollard J.A. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. Pediatr Blood Cancer. 2015;62(6):1048–54. doi:10.1002/pbc.25437.Tarlock K., Chang B., Cooper T., Gross T., Gupta S., Neuorf S., Adlard K., Ho P.A., McGoldrick S., Watt T., Templeman T., Sisler I., Garee A., Thomson B., Woolfrey A., Estey E., Meshinchi S., Pollard J.A. Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. Pediatr Blood Cancer. 2015;62(6):1048–54. doi:10.1002/pbc.25437.Glade Bender J.L., Lee A., Reid J.M., Baruchel S., Roberts T., Voss S.D., Wu B., Ahern C.H., Ingle A.M., Harris P., Weigel B.J., Blaney S.M. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034–43. doi:10.1200/JCO.2012.47.0914.Glade Bender J.L., Lee A., Reid J.M., Baruchel S., Roberts T., Voss S.D., Wu B., Ahern C.H., Ingle A.M., Harris P., Weigel B.J., Blaney S.M. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children’s oncology group phase I consortium report. J Clin Oncol. 2013;31(24):3034–43. doi:10.1200/JCO.2012.47.0914.Moreno L., Pearson A.D.J., Paoletti X., Jimenez I., Geoerger B., Kearns P.R., Zwaan C.M., Doz F., Baruchel A., Vormoor J., Casanova M., Pfister S.M., Morland B., Vassal G. Early phase clinical trials of anticancer agents in children and adolescents – an ITCC perspective. Net Rev Clin Oncol. 2017;14:497–507.doi:10.1038/nrclinonc.2017.59.Moreno L., Pearson A.D.J., Paoletti X., Jimenez I., Geoerger B., Kearns P.R., Zwaan C.M., Doz F., Baruchel A., Vormoor J., Casanova M., Pfister S.M., Morland B., Vassal G. Early phase clinical trials of anticancer agents in children and adolescents – an ITCC perspective. Net Rev Clin Oncol. 2017;14:497–507.doi:10.1038/nrclinonc.2017.59.

The authors declare that there are no conflicts of interest present.